The content on this site is intended for healthcare professionals only
Prof Margolese presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
Read the news article and watch the interview for more.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
OncoAlert round up July 28th to August 3rd, 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
